S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
Log in
NYSE:CNC

Centene Competitors

$60.93
-0.58 (-0.94 %)
(As of 01/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$60.70
Now: $60.93
$62.16
50-Day Range
$58.02
MA: $62.37
$69.75
52-Week Range
$43.96
Now: $60.93
$74.70
Volume3.53 million shs
Average Volume4.14 million shs
Market Capitalization$35.33 billion
P/E Ratio16.97
Dividend YieldN/A
Beta0.55

Competitors

Centene (NYSE:CNC) Vs. SNY, GSK, SYK, ISRG, GILD, and ANTM

Should you be buying CNC stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Centene, including Sanofi (SNY), GlaxoSmithKline (GSK), Stryker (SYK), Intuitive Surgical (ISRG), Gilead Sciences (GILD), and Anthem (ANTM).

Centene (NYSE:CNC) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Profitability

This table compares Centene and Sanofi's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Centene2.00%13.45%4.81%
Sanofi14.49%24.77%13.28%

Volatility and Risk

Centene has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500.

Institutional & Insider Ownership

91.5% of Centene shares are held by institutional investors. Comparatively, 6.9% of Sanofi shares are held by institutional investors. 1.9% of Centene shares are held by insiders. Comparatively, 1.0% of Sanofi shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Centene and Sanofi's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Centene$74.64 billion0.47$1.32 billion$4.4213.79
Sanofi$40.00 billion3.11$3.26 billion$3.3214.95

Sanofi has lower revenue, but higher earnings than Centene. Centene is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Centene and Sanofi, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Centene041112.81
Sanofi15502.36

Centene presently has a consensus price target of $83.8333, indicating a potential upside of 37.59%. Sanofi has a consensus price target of $57.00, indicating a potential upside of 14.85%. Given Centene's stronger consensus rating and higher possible upside, analysts plainly believe Centene is more favorable than Sanofi.

Summary

Centene beats Sanofi on 8 of the 14 factors compared between the two stocks.

Centene (NYSE:CNC) and GlaxoSmithKline (NYSE:GSK) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Profitability

This table compares Centene and GlaxoSmithKline's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Centene2.00%13.45%4.81%
GlaxoSmithKline18.50%29.60%7.11%

Volatility and Risk

Centene has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, GlaxoSmithKline has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.

Institutional & Insider Ownership

91.5% of Centene shares are held by institutional investors. Comparatively, 11.8% of GlaxoSmithKline shares are held by institutional investors. 1.9% of Centene shares are held by insiders. Comparatively, 10.0% of GlaxoSmithKline shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Centene and GlaxoSmithKline's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Centene$74.64 billion0.47$1.32 billion$4.4213.79
GlaxoSmithKline$43.10 billion2.27$5.93 billion$3.1712.28

GlaxoSmithKline has lower revenue, but higher earnings than Centene. GlaxoSmithKline is trading at a lower price-to-earnings ratio than Centene, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Centene and GlaxoSmithKline, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Centene041112.81
GlaxoSmithKline34602.23

Centene presently has a consensus price target of $83.8333, indicating a potential upside of 37.59%. Given Centene's stronger consensus rating and higher possible upside, analysts plainly believe Centene is more favorable than GlaxoSmithKline.

Summary

Centene beats GlaxoSmithKline on 8 of the 15 factors compared between the two stocks.

Centene (NYSE:CNC) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Earnings and Valuation

This table compares Centene and Stryker's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Centene$74.64 billion0.47$1.32 billion$4.4213.79
Stryker$14.88 billion6.05$2.08 billion$8.2629.00

Stryker has lower revenue, but higher earnings than Centene. Centene is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

91.5% of Centene shares are held by institutional investors. Comparatively, 71.5% of Stryker shares are held by institutional investors. 1.9% of Centene shares are held by insiders. Comparatively, 6.8% of Stryker shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Centene and Stryker, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Centene041112.81
Stryker271412.58

Centene presently has a consensus price target of $83.8333, indicating a potential upside of 37.59%. Stryker has a consensus price target of $227.4783, indicating a potential downside of 5.04%. Given Centene's stronger consensus rating and higher possible upside, analysts plainly believe Centene is more favorable than Stryker.

Volatility and Risk

Centene has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.

Profitability

This table compares Centene and Stryker's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Centene2.00%13.45%4.81%
Stryker12.35%20.94%8.77%

Summary

Stryker beats Centene on 10 of the 14 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and Centene (NYSE:CNC) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.

Earnings & Valuation

This table compares Intuitive Surgical and Centene's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$4.48 billion19.74$1.38 billion$9.9575.58
Centene$74.64 billion0.47$1.32 billion$4.4213.79

Intuitive Surgical has higher earnings, but lower revenue than Centene. Centene is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

86.5% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 91.5% of Centene shares are owned by institutional investors. 1.6% of Intuitive Surgical shares are owned by insiders. Comparatively, 1.9% of Centene shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Intuitive Surgical and Centene, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intuitive Surgical381002.33
Centene041112.81

Intuitive Surgical currently has a consensus price target of $736.0588, indicating a potential downside of 2.12%. Centene has a consensus price target of $83.8333, indicating a potential upside of 37.59%. Given Centene's stronger consensus rating and higher possible upside, analysts plainly believe Centene is more favorable than Intuitive Surgical.

Volatility and Risk

Intuitive Surgical has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Centene has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500.

Profitability

This table compares Intuitive Surgical and Centene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intuitive Surgical24.45%12.08%10.44%
Centene2.00%13.45%4.81%

Summary

Centene beats Intuitive Surgical on 8 of the 15 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Centene (NYSE:CNC) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Gilead Sciences and Centene, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences2141202.36
Centene041112.81

Gilead Sciences currently has a consensus price target of $94.3793, indicating a potential upside of 38.47%. Centene has a consensus price target of $83.8333, indicating a potential upside of 37.59%. Given Gilead Sciences' higher possible upside, equities research analysts plainly believe Gilead Sciences is more favorable than Centene.

Profitability

This table compares Gilead Sciences and Centene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
Centene2.00%13.45%4.81%

Institutional and Insider Ownership

76.4% of Gilead Sciences shares are owned by institutional investors. Comparatively, 91.5% of Centene shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by insiders. Comparatively, 1.9% of Centene shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Gilead Sciences and Centene's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.81$5.39 billion$6.1411.10
Centene$74.64 billion0.47$1.32 billion$4.4213.79

Gilead Sciences has higher earnings, but lower revenue than Centene. Gilead Sciences is trading at a lower price-to-earnings ratio than Centene, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Gilead Sciences has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Centene has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500.

Summary

Gilead Sciences beats Centene on 9 of the 15 factors compared between the two stocks.

Centene (NYSE:CNC) and Anthem (NYSE:ANTM) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Centene and Anthem, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Centene041112.81
Anthem041302.76

Centene currently has a consensus target price of $83.8333, indicating a potential upside of 37.59%. Anthem has a consensus target price of $353.3684, indicating a potential upside of 12.05%. Given Centene's stronger consensus rating and higher probable upside, analysts clearly believe Centene is more favorable than Anthem.

Profitability

This table compares Centene and Anthem's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Centene2.00%13.45%4.81%
Anthem4.22%18.45%7.27%

Institutional and Insider Ownership

91.5% of Centene shares are owned by institutional investors. Comparatively, 89.4% of Anthem shares are owned by institutional investors. 1.9% of Centene shares are owned by company insiders. Comparatively, 0.2% of Anthem shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Centene and Anthem's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Centene$74.64 billion0.47$1.32 billion$4.4213.79
Anthem$104.21 billion0.75$4.81 billion$19.4416.22

Anthem has higher revenue and earnings than Centene. Centene is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Centene has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, Anthem has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.

Summary

Anthem beats Centene on 9 of the 15 factors compared between the two stocks.


Centene Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
SNY
Sanofi
1.9$49.63-0.1%$124.28 billion$40.00 billion21.21
GlaxoSmithKline logo
GSK
GlaxoSmithKline
1.4$38.92-1.4%$97.63 billion$43.10 billion11.98
Stryker logo
SYK
Stryker
2.0$239.55-0.2%$90.02 billion$14.88 billion51.96Upcoming Earnings
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$752.01-1.1%$88.40 billion$4.48 billion85.65Earnings Announcement
Gilead Sciences logo
GILD
Gilead Sciences
2.7$68.16-1.8%$85.44 billion$22.45 billion70.27
Anthem logo
ANTM
Anthem
2.6$315.37-0.4%$78.43 billion$104.21 billion16.31Upcoming Earnings
Zoetis logo
ZTS
Zoetis
1.8$161.34-1.2%$76.68 billion$6.26 billion47.88
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$260.24-0.6%$75.69 billion$17.12 billion95.33Dividend Announcement
News Coverage
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$241.31-1.5%$62.75 billion$4.16 billion30.47Upcoming Earnings
Illumina logo
ILMN
Illumina
1.5$421.00-3.5%$61.47 billion$3.54 billion97.68
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.4$548.20-1.9%$58.50 billion$7.86 billion20.04Analyst Upgrade
Gap Down
MRNA
Moderna
1.6$147.00-10.9%$58.17 billion$60.21 million-90.74Insider Selling
Gap Down
TAK
Takeda Pharmaceutical
2.0$18.37-1.3%$57.92 billion$30.20 billion61.24Upcoming Earnings
High Trading Volume
HCA Healthcare logo
HCA
HCA Healthcare
2.1$168.43-0.9%$56.99 billion$51.34 billion17.03Upcoming Earnings
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.6$85.89-0.4%$53.53 billion$4.35 billion68.71Upcoming Earnings
Humana logo
HUM
Humana
2.5$404.00-0.3%$53.47 billion$64.89 billion12.95
Boston Scientific logo
BSX
Boston Scientific
2.2$36.78-0.7%$52.67 billion$10.74 billion14.09
Align Technology logo
ALGN
Align Technology
1.9$539.47-1.0%$42.54 billion$2.41 billion24.54
Biogen logo
BIIB
Biogen
2.1$275.54-2.2%$42.40 billion$14.38 billion9.12Analyst Revision
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$489.21-0.7%$41.73 billion$2.41 billion85.23Upcoming Earnings
Teladoc Health logo
TDOC
Teladoc Health
1.3$287.09-8.4%$41.62 billion$553.31 million-200.76Insider Selling
High Trading Volume
Baxter International logo
BAX
Baxter International
2.3$80.10-0.7%$40.92 billion$11.36 billion45.51
ALC
Alcon
1.4$74.85-1.1%$36.54 billion$7.51 billion-50.92
DexCom logo
DXCM
DexCom
1.9$376.39-1.7%$36.14 billion$1.48 billion155.53Insider Selling
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.8$161.32-1.0%$35.30 billion$4.99 billion37.69
BeiGene logo
BGNE
BeiGene
1.3$376.91-0.6%$34.37 billion$428.21 million-18.65
Zimmer Biomet logo
ZBH
Zimmer Biomet
2.1$159.31-1.1%$33.02 billion$7.98 billion995.75Analyst Report
News Coverage
Seagen logo
SGEN
Seagen
1.1$180.12-1.5%$32.58 billion$916.71 million70.91
ResMed logo
RMD
ResMed
1.4$221.68-2.8%$32.12 billion$2.96 billion47.57Upcoming Earnings
McKesson logo
MCK
McKesson
2.2$183.15-1.0%$29.41 billion$231.05 billion13.94Upcoming Earnings
GMAB
Genmab A/S
1.1$42.70-0.8%$27.99 billion$804.57 million33.10Analyst Downgrade
News Coverage
BNTX
BioNTech
1.1$110.61-2.0%$25.03 billion$121.63 million-55.31Analyst Downgrade
Cerner logo
CERN
Cerner
2.2$80.50-0.7%$24.68 billion$5.69 billion31.45
Fresenius Medical Care AG & Co. KGaA logo
FMS
Fresenius Medical Care AG & Co. KGaA
1.6$41.79-1.1%$24.48 billion$19.58 billion16.58
Exact Sciences logo
EXAS
Exact Sciences
1.6$153.93-2.6%$23.15 billion$876.29 million-69.65Analyst Revision
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
1.9$300.26-0.1%$22.20 billion$1.84 billion79.22
Incyte logo
INCY
Incyte
1.7$100.50-2.6%$22.01 billion$2.16 billion-64.01
Laboratory Co. of America logo
LH
Laboratory Co. of America
1.2$225.44-1.5%$21.96 billion$11.55 billion26.24
AmerisourceBergen logo
ABC
AmerisourceBergen
1.9$106.87-0.8%$21.83 billion$189.89 billion-6.37
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.6$175.69-1.9%$20.41 billion$219.75 million-22.44Analyst Downgrade
Hologic logo
HOLX
Hologic
1.9$76.34-0.8%$19.62 billion$3.78 billion18.18Upcoming Earnings
Smith & Nephew logo
SNN
Smith & Nephew
1.8$44.60-1.7%$19.56 billion$5.14 billion21.86Gap Up
GDRX
GoodRx
1.2$49.88-10.8%$19.47 billion$388.22 million0.00Analyst Report
High Trading Volume
Gap Down
Catalent logo
CTLT
Catalent
1.7$115.73-0.9%$19.06 billion$3.09 billion73.71Upcoming Earnings
Insulet logo
PODD
Insulet
1.3$288.91-0.5%$19.05 billion$738.20 million656.63
The Cooper Companies logo
COO
The Cooper Companies
1.7$383.65-1.0%$18.85 billion$2.43 billion79.76Analyst Report
TXG
10x Genomics
1.3$183.25-2.0%$18.39 billion$245.89 million-135.74Analyst Downgrade
CureVac logo
CVAC
CureVac
0.6$104.50-1.7%$18.39 billionN/A0.00
Teleflex logo
TFX
Teleflex
2.0$382.14-1.1%$17.80 billion$2.60 billion49.18
AVTR
Avantor
1.8$30.69-0.6%$17.74 billion$6.04 billion255.75
This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.